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SUMMARY 
Clinical spectrum of Alzheimer’s disease 
Caroline Lucie Mouselli 
 
The incidence of Alzheimer’s disease (AD) increases exponentially with age. 
Therefore, it becomes a major public health problem since the population is getting 
older, and the cost of caring increases. Cognitive deficits in AD appear and progress 
insidiously, but the rate of progression can vary. The average life expectancy has 
been reported to be between three and eight years. Clinical assessment and 
neuropsychological testing are necessary initial tools for the diagnosis of AD. 
Memory impairment, specifically loss of episodic memory (memory of recent events), 
is an essential feature of AD and is usually its first manifestation. Deficits in other 
cognitive domains may appear with or after the development of memory impairment. 
Language function and visuospatial skills tend to be affected relatively early, while 
deficits in executive function and behavioural symptoms often manifest later in the 
disease course. Neuropsychiatric and behavioural symptoms are common in middle 
and late stages of AD. Noncognitive neurologic deficits (pyramidal and 
extrapyramidal motor signs, myoclonus, and seizures) can occur in late stages of 
AD, but are uncommon in early and middle stages. Atypical presentations of AD may 
occur. These include a visual variant (posterior cortical atrophy), primary progressive 
aphasia (PPA) and behavioural variant AD (bvAD). AD progresses through three 
stages: an early, preclinical stage with no symptoms; a middle stage or mild 
cognitive impairment (MCI); and a final stage marked by symptoms of dementia 
(apparent AD). Diagnostic tests (basic laboratory tests and neuroimaging) are 
performed initially to exclude other (treatable) causes. Recently discovered 
biomarkers may help in early and differential diagnosis as well as prognosis of AD. 
Keywords: Alzheimer’s disease, atypical, Mild cognitive impairment, diagnosis, 
biomarkers. 
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INTRODUCTION 
 
Dementia is a clinical syndrome characterised by a cluster of symptoms and 
signs manifested by difficulties in memory, disturbances in language, psychological 
and psychiatric changes, and impairments in activities of daily living.  
Alzheimer disease (AD) is the most common cause of dementia. According to the 
Alzheimer’s Association[1], approximately 60 to 80% of cases of dementia among the 
elderly population are caused by AD which is to be differentiated from other forms of 
dementia, such as vascular cognitive impairment (VCI), dementia with Lewy bodies 
(DLB), frontotemporal lobar degeneration (FTLD) and dementia caused by 
Parkinson’s disease among others. 
AD is a specific disease that affects about 6% of the population aged over 65 
and increases in incidence with age. It is progressive neurodegenerative disorder 
beginning with episodic memory impairment, but inevitably affecting all cognitive 
functions and leading to premature death.  
With aging being the main risk factor of the disease, the probability of being 
affected doubles every 5 years after the age of 65. It becomes a major public health 
problem as the population ages, and the cost of caring increases. The World 
Alzheimer Report 2013[2] estimated that over 35 million people worldwide currently 
live with this condition and this number is expected to double by 2030 and more than 
triple by 2050 to 115 million. 
So, dementia is one of the biggest global public health challenges facing our 
generation. In the 2010 World Alzheimer Report[3], Alzheimer’s Disease International 
(ADI) estimated that the annual societal costs of dementia worldwide were US$604 
billion, or 1% of the aggregated worldwide Gross Domestic Product (GDP) and it 
predicted a near doubling in worldwide societal costs from US$604 billion in 2010 to 
US$1,117 billion by 2030. Moreover, from a patient perspective, this disease is 
leading to complete dependence for basic functions of daily life, and decrease 
tremendously their quality of life.  
Additionally, patients with AD present diagnostic and management challenge. 
The benefits of early investigation and diagnosis of AD include early access to 
pharmacological symptomatic treatments, initiation of psychosocial support, and 
treatment of comorbid conditions.  
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This is why in 1984, a work group on the diagnosis of AD was established by 
the National Institute of Neurological and Communicative Disorders and Stroke 
(NINCDS) and the Alzheimer’s Disease and Related Disorders Association 
(ADRDA)[4]. The aim of the work group was to define clinical diagnostic criteria for 
AD to serve as a clinical basis for diagnosis of AD. They conceptualized AD as a 
dual clinical-pathological entity, which requires 1/ a clinical phenotype typically 
centred on the presence of a progressive dementia that includes episodic memory 
impairment as a defining feature and involvement of other cognitive domains or 
skills, and 2/ specific neuropathological changes that usually include intraneuronal 
(neurofibrillary tangles) and extracellular parenchymal lesions (senile plaques), 
which are often accompanied by synaptic loss and vascular amyloid deposits and 
can only be verified by post-mortem histological examination of brain tissue[4]. They 
classified AD as definite (clinical diagnosis with histologic confirmation), probable 
(typical clinical syndrome without histologic confirmation), or possible (atypical 
clinical features, but no alternative diagnosis apparent and no histologic 
confirmation). These criteria have been reliable for the diagnosis of probable AD, 
and across more than a dozen clinical pathological studies have had a sensitivity of 
81% and specificity of 70%[5]. 
However, in the intervening 30 years tremendous progression has been made 
in the understanding of the AD pathological process. So in April, 2011, the diagnostic 
criteria for AD were revised to reflect a deeper understanding of the disease[6]. The 
new guidelines differ from the 1984 diagnostic criteria in a few key ways. Three main 
points are highlighted:  
• They reflect a better understanding of dementia and the distinctions and 
associations between typical Alzheimer and non-Alzheimer’s dementias, as 
well as recognize the potential use of biomarkers as indicators of underlying 
brain disease to diagnose AD.  
• They expand the criteria for Alzheimer’s dementia beyond memory loss as the 
first or only major symptom: they recognize that there are several nonamnesic 
presentations of the pathophysiological process of AD, the most common 
ones being the syndrome of posterior cortical atrophy[7] and the primary 
progressive aphasia[8].  
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• They recognize that AD progresses on a spectrum with three stages: an early, 
preclinical stage with no symptoms; a middle stage of mild cognitive 
impairment (MCI); and a final stage marked by symptoms of dementia 
(apparent AD).  
Each of these 3 points will be developed in the next 3 chapters of this review paper. 
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I. TYPICAL PRESENTATION OF AD 
 
Important concepts about dementia will be developed in this chapter: the 
clinical evaluation of cognitive impairment with history taking and neuropsychological 
testing, the causes and differential diagnoses of dementia, and finally investigations 
to rule out reversible causes of dementia. Then specificities on AD will be explained: 
its clinical findings, clinical criteria and progression. 
 
I. 1. Clinical features and diagnosis of dementia 
 
I.1.1 History and clinical findings 
 
The National Institute on Aging and the Alzheimer’s Association clinical 
guidelines revised in April 2011 criteria for dementia[6]. The diagnosis is made when 
there are cognitive or behavioural (neuropsychiatric) symptoms that disrupt daily 
function (work, usual activities) and represent a decline from previous levels of 
functioning and performing. The key to the reliable identification of cognitive 
impairment is to integrate three components:  
• history taking from the patient and a collateral account from a carer, 
• physical examination and observation of the patient, 
• and assessment of cognition with standardised tests either a “bedside” 
mental status examination or neuropsychological testing. 
The cognitive or behavioural impairment involves a minimum of two domains 
including memory, language, executive function, or visuospatial skills.  
In the amnestic presentation there is impaired ability to acquire and remember new 
information. The patient with this presentation asks repetitive questions during 
conversation, misplaces personal belongings, forgets events or appointments, and 
gets lost on a familiar route.  
Other cognitive area that can be involved is the executive function with 
presentation of impaired reasoning and handling of complex tasks, poor judgment if 
dysfunction is present: the patient presents with poor understanding of safety risks, 
inability to manage finances, poor decision-making ability, inability to plan complex or 
sequential activities.  
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Also, impaired visuospatial abilities may be found: the patient has poor ability 
to recognize faces or common objects or to find objects in direct view despite good 
acuity, to operate simple implements, or orient clothing to the body.  
Additionally, language impairment can also be found: symptoms include 
difficulty of finding common words while speaking, hesitations; speech, spelling, and 
writing errors.  
Finally, behaviour can change such as uncharacteristic mood fluctuations, 
agitation, impaired motivation and initiative, apathy, loss of drive, social withdrawal, 
decreased interest in previous activities, loss of empathy, compulsive or obsessive 
behaviours, socially unacceptable behaviours.  
 
I.1.2. Causes and differential diagnoses of dementia 
 
It is necessary to rule out other causes of dementia or other systemic or brain 
diseases that could account for the decline in cognition. The four main causes of 
dementia are AD, vascular cognitive impairment (VCI), frontotemporal lobar 
degeneration (FTLD) and dementia with Lewy bodies (DLB).  
Core clinical features of DLB are fluctuating cognitive impairment (seen in 50-
75% of patients), visual hallucinations, and parkinsonism (seen in 25-50% of patients 
at diagnosis)[9]. Its supportive features are repeated falls, syncope, transient loss of 
consciousness, neuroleptic sensitivity, systematized delusion, hallucination of other 
modalities, rapid eye movement (REM) sleep behaviour disorder, and depression.   
The clinical features of FTLD are described with the emphasis on prominent 
personality and behavioural changes with less prominent memory loss early in the 
course comparing to AD[10]. Frequently, FTLD is misdiagnosed as personality 
disorders or late-onset psychiatric disorders. Common conduct disturbances are loss 
of personal awareness, inappropriate social behaviour, disinhibition, impulsivity, 
distractibility, hyperorality (excessive eating), social withdrawal, stereotyped or 
preservative behaviour, and speech output change (reduction of speech, stereotyped 
speech, and echolalia). The physical examination usually reveals early prominent 
primitive or frontal reflexes.  
VCI is caused primarily by ischemic strokes. The most common form is due to 
small vessel cerebrovascular disease. Diagnosis is most specific if there is a stroke-
like course of illness, neurologic signs of stroke on examination, and imaging 
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evidence of stroke. However, the course of illness may appear smoothly progressive, 
and there may be no elementary neurologic signs. The presentation of cognitive 
impairment in VCI may be quite distinct from AD, especially early in the disease 
course, with prominent deficits in executive dysfunction causing significant disability, 
even while memory impairment is quite mild and before the patient reaches criteria 
for dementia. There is considerable overlap between AD and VCI with regard to 
comorbidity as well as shared risk factors and even pathogenesis. The combination 
of pathologies may be more common than either in isolation (mixed dementia).  
Also, it’s important to rule out prion disease, neoplasm, or metabolic disorders 
that present with very rapid cognitive decline that occurs over weeks or months. 
 
Two main differential diagnoses of dementia, delirium and depression, should 
be also ruled out.  
Features of delirium include poor attention (distractibility or inability to focus), 
incoherent speech (hard to fully understand what the patient is trying to say), and 
altered level of alertness (sleepiness or agitation). The key is substantial change or 
fluctuation in mental status over hours or days: this is the cardinal feature of delirium. 
Drugs are a common cause of delirium in older people, and a medication review is 
therefore essential.  
Features of depression include low mood, loss of interest and diminished 
capacity for enjoyment, poor self-care, and a negative outlook with feelings of 
hopelessness that can include suicidal thoughts. However, it is important to be 
aware that somatic symptoms such as reduced energy, poor appetite and insomnia 
are more prominent than depressed mood. 
 
I.1.3. Objective clinical assessment of dementia 
 
It is valuable to get a first impression of general cognitive functioning. Simple 
questions and tasks such as those of the mini mental state examination (MMSE) 
provide insight into the level and severity of cognitive functioning of a patient[11]. It is 
the most widely used cognitive test for dementia in clinical practice. The examination 
takes approximately 7 minutes to complete. It tests a broad range of cognitive 
functions including orientation, recall, attention, calculation, language, and 
constructional praxis (figure I.1). The MMSE has a maximum score of 30. A MMSE 
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score between 20 and 26 is associated with mild functional dependence, such as 
difficulty managing finances. Moderate AD (MMSE score between 10 and 20) is 
associated with more immediate dependency, such as inability to drive, difficulty with 
hygiene and shopping, and remote memory impairment. Severe disease (MMSE 
score under 10) correlates with a state of total dependence and need for constant 
supervision. While proven reliable, its validity is less secure unless adjusted scoring 
methods are used to address the potential for educational and age bias[12]. So with a 
high level of education and younger age, a higher score may already be suggestive 
of cognitive dysfunction. Another inconvenient is that the MMSE is relatively 
insensitive to early or mild forms of dementia. 
The clock drawing test (figure I.2) is a screen for visuospatial, constructional 
praxis and frontal/executive impairment. The patient is asked to draw a clock. 
Inability to correctly space the numbers around the circle can be due to a 
visuospatial impairment, neglect, or a planning deficit. He is then asked to set the 
time at 10 after 11 which tests the patients capacity to compute that the minute hand 
should be pointing to the number 2, rather than 10 (a frontal/executive function). The 
advantage is the relative independence from bias due to intellect, language or 
cultural factors. 
Neuropsychological testing should be performed when the routine history and 
bedside mental status examination cannot provide a confident diagnosis. 
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Figure I.1: The mini mental state examination (MMSE). 
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Figure I.2: Clock drawings by patients with AD: the patient is asked to draw a clock 
and set the time at 10 after 11. 
 
I.1.4. Criteria for dementia 
 
Dementia is fundamentally a clinical diagnosis. Criteria for the diagnosis of 
dementia have been established by the National Institute on Aging and The 
Alzheimer's Association[6].  They are defined by the following characteristics:  
• interference with ability to function at work or at usual activities, 
• a decline from a previous level of functioning and performing, 
• cognitive impairment established by history-taking from the 
patient and a knowledgeable informant; and objective bedside 
mental status examination or neuropsychological testing, 
• cognitive impairment involving a minimum of two of the following 
domains :  
- impaired ability to acquire and remember new information, 
- impaired reasoning and handing of complex tasks, poor 
judgment, 
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- impaired visuospatial abilities, 
- impaired language functions, 
- changes in personality, behaviour or comportment. 
Moreover, these symptoms should not be explained by delirium or major psychiatric 
disorder. 
 
I.1.5. Investigations 
 
The aim of further investigations is to detect potentially reversible causes of 
cognitive impairment such as vitamin B12 deficiency, hypothyroidism or electrolytes 
abnormalities (e.g. hypercalcemia). The National Institute for Health and Clinical 
Excellence (NICE) dementia guidelines recommended performing the following 
blood tests for all patients at first presentation[13]:  
• a full blood count, 
• T4 and thyroid stimulating hormone (TSH) blood levels, 
• biochemical screen for electrolytes abnormalities, 
• urea and creatinine plasma level, 
• plasma glucose level, 
• vitamin B12 and folate level, 
• clotting factors and albumin level in the plasma, 
• blood sedimentation rate and C reactive protein (CRP). 
Routine chest X-ray and electrocardiogram should be performed as well. 
 
Other possible blood tests, though not routinely requested in primary care, 
depend on the patient profile (young age, risk factors for sexually transmitted 
diseases such as having multiple partners or having a history of sexually transmitted 
infection) or on clinically identified causes on physical examination. They include: 
• syphilis serology : TPHA-VDRL, 
• human immunodeficiency virus (HIV) serology, 
• caeruloplasmin for Wilson's disease. 
Other possible specialist investigations include: 
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• cerebrospinal fluid (CSF) examination if Creutzfeldt-Jakob disease 
(CJD) or other forms of rapidly progressive dementia are 
suspected, 
• electroencephalography (EEG) is not routinely indicated but should 
be considered in suspected delirium, FTLD or CJD or associated 
seizure disorder in those with dementia. 
Structural imaging such as MRI or CT scan, are performed to exclude other 
cerebral pathologies and help establish the subtype of dementia. It may help to 
identify treatable causes such as subdural haematoma, normal pressure 
hydrocephalus, cerebral tumours etc. Finally, assessment of co-morbidities is 
essential for the diagnosis and management of dementia such as alcohol 
intoxication, cardiovascular risk factors (diabetes and dyslipidaemia), malnutrition, 
and age-related diseases (visual or auditory deficit, abnormal transit, mainly 
constipation and dehydration). 
 
I. 2. Clinical features and diagnosis of AD 
 
Now that criteria for dementia have been developed in the previous chapter, 
further clinical and nonclinical investigations should be done to make the final 
diagnosis of AD, the most common cause of dementia. To better understand the 
clinical features and the diagnosis of AD, the history of the discovery of dementia 
and its pathophysiology will be explained in the next chapter. 
 
I.2.1. Overview of the pathophysiology of AD 
 
The initial case reported by Aloïs Alzheimer, Auguste Deter (figure I.3), 
presented with behavioural disorders, psychosis and delusions in combination with 
dementia. These symptoms matched the definition of what was then called 
dementia, but she was very young to be displaying them, so he diagnosed her as 
having “presenile dementia”. When the patient died, Dr. Alzheimer sampled thin 
slices of this brain tissue, stained them with silver salts, and examined them under 
the microscope. He observed two types of abnormal deposits one outside the nerve 
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cells (in modern terminology, “amyloid plaques"), the other inside (now known as 
“neurofibrillary tangles"), which are the pathologic anomalies that now hallmark AD. 
 
 
Figure I.3: the case of Auguste Deter reported by Aloïs Alzheimer. 
 
Nowadays, although the pathophysiology of AD still remains controversial, it 
has been clear that the pathological manifestations of AD include diffuse and neuritic 
extracellular amyloid plaques and intracellular neurofibrillary tangles[14] accompanied 
by reactive microgliosis, dystrophic neurites, and loss of neurons and synapses[15]. 
The regional evolution of AD pathology in terms of amyloid deposition and 
neurofibrillary tangles at several stages of the disease was described by Braak and 
Braak[16], using post-mortem brain tissue. While these pathological lesions do not 
fully explain the clinical features of the disease, it has been hypothesized that 
alterations in the production and processing of amyloid beta (Aβ) protein may be the 
principal initiating factor[17]. The underlying causes of these multifaceted changes 
remain unknown, but advancing age, genetic and nongenetic antecedent factors are 
thought to play important roles.  
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The genetic contribution to AD risk remains poorly understood despite major 
advances in the 1990’s in the identification of three genes that cause early-onset AD 
(EOAD) and one significant genetic risk factor for late-onset AD (LOAD)[18]. The first 
progress in understanding the genetic basis of AD resulted from studies of families 
displaying autosomal dominant inheritance of the disorder. In these families, affected 
individuals typically develop symptoms of AD between the ages of 30 and 60 years. 
Early studies[19] in families with autosomal dominant AD identified causative 
mutations in the three genes: amyloid precursor protein (APP)[20], presenilin 
1(PSN1)[21] and prenisilin 2 (PSN2)[22]. The genetic basis of late-onset Alzheimer 
disease (LOAD) is more complex, with susceptibility conferred by a variety of more 
common but less penetrant genetic factors, likely interacting with environmental and 
epigenetic influences. To date, the only established genetic risk factor for late-onset 
disease is apoprotein E (APOE)[23]. The APOE gene is located on chromosome 19 
and exists in three alleles: epsilon 2, 3, and 4. APOE is a susceptibility gene, not a 
determinative gene. Patients homozygous for this allele are much more likely but not 
absolutely destined to develop dementia. In addition, almost 40% of patients with AD 
do not carry APOE ε4[24].  
 
I.2.2. Clinical features of AD 
 
The amnestic presentation often prevails, but nonamnestic presentations can 
occur (see chapter II). The typical early cognitive impairment found in AD is memory 
involvement. It can be assessed by means of neuropsychological tests. In AD, 
declarative memory for facts and events, which depend on mesial temporal and 
neocortical structures are profoundly affected, while subcortical systems supporting 
procedural memory and motor learning are relatively spared until quite late in the 
disease. A subset of declarative memory, that of specific events and contexts 
(episodic memory) is more profoundly impaired in early AD, compared with memory 
for facts such as vocabulary and concepts (semantic memory), which often becomes 
impaired later. Semantic memory is encoded in neocortical (nonmesial) temporal 
regions. Within episodic memory, there is a distinction between immediate recall 
(mental rehearsal of a phone number), memory for recent events (which comes into 
play once material that has departed from consciousness must be recalled), and 
memory of more distant events. Memory for recent events, served by the 
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hippocampus, entorhinal cortex, and related structures in the mesial temporal lobe, 
is prominently impaired in early AD. In contrast, immediate memory (encoded in the 
sensory association and prefrontal cortices) is spared early on, as are memories that 
are consolidated for long periods of time (years), which can be recalled without 
hippocampal function. The early memory deficit in AD is most precisely described as 
anterograde long-term episodic amnesia. Memory deficits develop insidiously and 
progress slowly over time, evolving to include deficits of semantic memory and 
immediate recall. Impairments of procedural memory appear only in late stages of 
AD. There are numerous tests to assess memory and follow up its progression. 
 
I.2.3. Neurocognitive assessment in AD 
 
Testing orientation to time and place and asking the patient about events of 
the day are useful tools in the office or at the bedside to assess recent memory 
which involves the learning of new material. A more explicit test of recent memory, is 
asking patient to remember three to four words, having them repeat to ensure 
normal attention/immediate memory, and then ask them to recall the words after 5 to 
10 minutes of distraction. For patients who are unable to recall the original words, 
category hints ("animal") or multiple-choice cues ("cow, horse, or dog") can be given 
to further assess the severity of the deficit. Longer lists of 8 to 10 words can also be 
used to increase the sensitivity of the test. Normal older adults should be able to 
remember three out of three words without cues and up to eight words with cues. 
Impaired ability to recall objects with selective cues (hints) represents a more severe 
deficit and one that may be particularly specific for AD in its early presentation. 
           The "three-words three-shapes" memory test is another test of recent memory 
that can be useful in the office setting[25]. In this test, patients are asked to copy three 
words (eg, justice, courage, thirst) along with three abstract shapes. Delayed recall is 
tested in 5, 15, and 30 minutes with re-exposure to the stimuli as needed. If recall is 
faulty, multiple-choice recognition is tested. 
 
Retrieval of remote memories can be tested by asking for the names of 
presidents from the country they are from in reverse order as far back as the patient 
can remember, or by asking about important historical events and dates as well as 
sporting events and popular television shows. The patient can also be asked about 
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details of personal life such as his or her birth date, the names and ages of children 
and grandchildren, and work history, assuming independent verification is available. 
Asking the patient the meanings of words, phrases, and symbols assesses semantic 
memory.  
 
I.2.4. Criteria for the diagnosis of AD 
 
Criteria for the diagnosis of probable AD dementia have been established by 
the National Institute on Aging and the Alzheimer's Association[6]. 
To make the diagnosis of probable AD, the patient should present the criteria for 
dementia (see part I.1.4) associated with other core criteria that include:  
• a insidious onset, 
• a clear-cut history of worsening, 
• with initial and most prominent cognitive deficits being one of the 
following : 
- amnestic presentation, 
- or nonamnestic presentations which include either : 
o a language presentation: prominent word-finding deficits, 
o a visuospatial presentation: visual cognitive deficits, 
o or a dysexecutive presentation: prominent impairment of 
reasoning, judgment and/or problem solving 
Also, differential diagnoses have to be ruled out. There should be no evidence 
of substantial concomitant cerebrovascular disease, core features of DLB, prominent 
features of behavioural variant FTLD or prominent features of semantic or nonfluent 
variants of primary progressive aphasia, or evidence of another concurrent, active 
neurologic or non-neurologic disease or use of medication that could have a 
substantial effect on cognition. 
 
Additionally, the National Institute on Aging and the Alzheimer's Association 
established criteria for possible AD dementia[6]. Possible AD includes the following 
clinical features: 
• atypical onset, presentation, or progression of dementia without known 
aetiology, 
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• presence of another potentially causative systemic or neurologic 
disorder that is not thought to be the aetiology of dementia in this case, 
• progressive deterioration in a single cognitive domain in the absence of 
any other aetiology. 
 
I.2.5. Clinical course of AD 
 
AD progresses insidiously. The progress of the disease can be measured with 
mental status scales such as the MMSE. The clinical course is not necessarily linear, 
however, a number of studies have found that patients decline 3 to 3.5 points on 
average on the MMSE each year[26]. A minority (<10%) of AD patient presents with a 
specific form of AD called rapidly progressive AD which is defined as having a 
decline of more than 6 points on annual MMSE[27]. An older age of onset of AD (>80 
years) may be associated with a slower rate of decline compared to younger 
patients[28]. The MMSE has limitations for assessing progressive cognitive decline in 
individual patients over time. Small changes of 2 points or less in MMSE can be 
interpreted only with great uncertainty. They have a reasonable probability of being 
caused by measurement error, regression to the mean or practice[29]. The reported 
median survival after diagnosis of AD is 4.2 years for men and 5.7 years for women 
with AD[30]. Patients generally succumb to terminal-stage complications that relate to 
advanced debilitation, such as dehydration, malnutrition, and infection. 
 
Deficits in other cognitive domains may appear with or after the development 
of memory impairment. Language function and visuospatial skills tend to be affected 
relatively early, while deficits in executive function often manifest later in the disease 
course. These deficits appear and progress insidiously. 
The first manifestations of language dysfunction usually include word-finding 
difficulties, circumlocution, and reduced vocabulary in spontaneous speech and 
anomia on confrontational naming tests. This progresses to include agrammatism, 
paraphasic errors, impoverished speech content, and impaired comprehension.  
Loss of visuospatial skills is an early feature of AD and manifests as 
misplacement of items and difficulty navigating in first unfamiliar then familiar terrain. 
Visual agnosia (inability to recognize objects) and prosopagnosia (inability to 
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recognize faces) are later features. Visuospatial skills may be tested by doing a clock 
drawing test (figure I.2). 
Impairment in executive function may be subtle rather than frank; family 
members and coworkers may find them less motivated and engaged. In addition to 
poor insight, reduced ability for abstract reasoning may be elicited. As the disease 
progresses, a more manifest alteration of personality, poor judgment and planning, 
and an inability to complete tasks typically emerges. 
 
I.2.6. Neuroimaging  
 
Brain structural imaging, preferably with magnetic resonance imaging (MRI), 
is indicated in the evaluation of patients with suspected AD. On structural 
neuroimaging, both generalized and focal atrophy, as well as white matter lesions is 
noted. Also, medial temporal lobe atrophy, particularly the hippocampal formation 
and the amygdala have been shown to be reduced in AD (Figure I.4)[31]. However, 
this finding is not specific for AD, as hippocampal atrophy also occurs in other 
common dementias such as VCI, DLB, and FTLD. Also, it is not clear that this finding 
adds to the accuracy of the diagnosis over the clinical assessment alone[32]. Brain 
MRI can also document potential alternative diagnoses including cerebrovascular 
disease, other structural diseases (chronic subdural hematoma, cerebral neoplasm, 
normal pressure hydrocephalus), and regional brain atrophy suggesting FTLD. 
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Figure I.4 : Tl-weighted MRI scan of a patient with AD. Generalized brain atrophy 
and loss of gray matter affecting the hippocampus (red arrow), entorhinal cortex 
(green arrow) and perirhinal cortex (blue arrow). Abbreviation: AD, Alzheimer 
disease. 
 
Positron emission tomography with [18F] fluorodeoxyglucose (FDG-PET)[33], 
functional MRI (fMRI)[34], perfusion MRI, or perfusion single photon emission 
computed tomography (SPECT) reveals distinct regions of low metabolism and 
hypoperfusion in AD. These areas include the hippocampus, the precuneus (mesial 
parietal lobes) and the lateral parietotemporal cortex. Clinical studies suggest that 
FDG-PET may be useful in distinguishing AD from FTLD[35].  
On SPECT scanning, reductions of blood flow and oxygen use can be found 
in the temporal and parietal neocortex in patients with AD, but it is not commonly 
used to assess AD.  
On FDG-PET scanning, glucose hypometabolism is likely to be caused by a 
combination of neuronal cell loss and decreased synaptic activity in AD. Patients 
with AD have characteristic temporoparietal glucose hypometabolism, the degree of 
which is correlated with the severity of dementia[36]. With disease progression, frontal 
involvement may be evident. The limited availability of PET in most medical centres 
is a current obstacle to widespread use.  
The most significant advance in dementia imaging in recent years has been 
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the development of in vivo amyloid plaque labelling compounds. The most widely 
studied in vivo amyloid labelling tracer at this point is the PET ligand {N-methyl-
11C}2-(4'-methylaminophenyl)-6-hydroxybenzothiazole also know as Pittsburgh 
Compound B or PiB[37]. PiB binds to fibrillar amyloid primarily in neuritic and diffuse 
plaques. In vivo PiB studies demonstrate a roughly two-fold increase in tracer 
retention in AD patients compared to most cognitively normal elderly subjects. 
Moreover, the topographic distribution of PiB retention matches that expected on the 
basis of autopsy studies of regional fibrillar plaque distribution[38]. Greatest retention 
values are seen in prefrontal and lateral temporoparietal cortex, posterior 
cingulate/precuneus, and striatum[39]. So PiB-PET is under investigation as an in vivo 
biomarker to positively diagnose AD: it can assess the level of certainty for AD (see 
chapter I.2.7), aid in prognosis, and differentiate AD from other causes of dementia.  
 
It should be noted that the pathological features of other causes of dementia 
could exist in combination with AD (i.e. dementia with Lewy bodies, DLB and 
vascular cognitive impairment, VCI), particularly among individuals at an advanced 
age, which is particularly challenging from a diagnostic perspective[51]. Because AD 
pathology frequently coexists with vascular pathology, particularly at older ages, both 
may contribute to cognitive dysfunction (mixed dementia). Thus, during life, it may be 
difficult to determine which pathological feature is the primary cause of the cognitive 
impairment. 
 
I.2.7. Biomarkers of AD 
 
Over the past years, the potential use of biomarkers has been recognized as 
valuable tool for early and accurate diagnosis of AD[40]. The major AD biomarkers 
that have been widely investigated at this time may be broken into two classes 
based on the biology which they measure. The first category is biomarkers of brain 
Aβ protein deposition. The two major biomarkers are low CSF Aβ42 and a positive 
PiB-PET amyloid imaging[41]. The second category is that of biomarkers of 
downstream neuronal degeneration or injury. The three major biomarkers in this 
category are elevated CSF tau, both total tau (t-tau) and phosphorylated tau (p-tau); 
decreased 18FDG uptake on PET in temporo-parietal cortex; and disproportionate 
atrophy on structural magnetic resonance imaging in medial temporal lobe, and 
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hippocampus by volumetric MRI measurements[40]. Each of these five biomarkers is 
validated enough to be used in currently active therapeutic trials and large 
multicentered observational studies. Both CSF Aβ42 and amyloid PET imaging are 
biomarkers of brain Aβ plaque deposition. Excellent correspondence has been seen 
between Pittsburgh compound B (PiB) binding and fibrillar Aβ deposition in the brain 
(or cerebral vasculature) found on autopsy (figure I.5)[37]. 
 
 
Figure I.5: Axial PET amyloid imaging with Pittsburgh Compound B (PiB) (upper) and 
coronal structural MRI (lower) in three older patients. Regions of red and yellow 
indicate high Pittsburgh Compound B retention, indicating presence of amyloid 
deposition. (A) A cognitively normal individual with no evidence of Aβ on PET 
amyloid imaging with PiB and no evidence of atrophy on MRI. (B) A cognitively 
normal individual who has no evidence of neurodegenerative temporal atrophy on 
MRI, but has significant Aβ deposition on PET amyloid imaging. (C) An individual 
who has dementia and a clinical diagnosis of AD, a positive PET amyloid imaging 
study, and neurodegenerative atrophy of the temporal lobe on MRI.  
Abbreviations: MRI, Magnetic resonance imaging; Aβ, amyloid-beta ; PiB, Pittsburgh 
compound B. Adapted from Jack et al., 2010[42]. 
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Low concentrations of CSF Aβ correlate with both the clinical diagnosis of AD 
and Aβ neuropathology at autopsy[43]. CSF tau is an indicator of tau pathological 
changes and associated neuronal injury and concentrations of both p-tau and t-tau 
increase in AD[44]. FDG-PET studies in patients with AD show a specific topographic 
pattern of decreased glucose uptake in a lateral temporoparietal (figure I.6) and 
posterior cingulate, precuneus distribution[45]. 
 
 
Figure I.6. : Changes revealed by 18F-FDG-PET scanning in the brain, patterns 
characteristic of metabolic activity in cognitively normal individuals and patients with 
late-onset AD. In comparison with people aging normally (left), individuals with late-
onset AD (right) show decreased bilateral glucose metabolism, particularly in the 
temporal and parietal regions. Abbreviations: AD, Alzheimer disease; FDG, 2-fluoro-
2-deoxy-D-glucose; PIB, Pittsburgh compound B. 
 
Finally, structural MRI can provide measures of cerebral atrophy, which is 
caused by dendritic pruning and loss of synapses and neurons[46] which correlate 
with rates of cognitive decline[47]. Manual hippocampal volumetry is currently the 
best-established biomarker for AD in the fields of structural imaging. Significant 
atrophy of the hippocampal formation can be demonstrated by MRI even in 
preclinical stages of AD and predict later conversion to AD[48-49]. Automated data 
driven methods such as voxel-based volumetry (VBM), deformation-based 
morphometry (DBM) and the measurement of cortical thickness are currently being 
investigated to detect regional changes. 
	   28	  
I.2.8 Classification of AD 
 
In persons who meet the core clinical criteria for probable AD dementia, 
positive biomarker may increase the certainty that the basis of the clinical dementia 
syndrome is the AD pathophysiological process. Hence, the National Institute on 
Aging and The Alzheimer's Association included these biomarkers for the 
pathophysiological process of AD in the diagnostic criteria[6]. 
 
Table I.1: Diagnostic Criteria for AD Dementia 
Diagnosis Likehood of 
AD aetiology 
Aβ 
(PET or CSF) 
Neuronal injury (tau, 
FDG-PET, sMRI) 
Probable AD dementia    
Clinical evidence only Uninformative Conflicting / Indeterminate / Unavailable 
With Biomarker 
evidence 
Intermediate 
Intermediate 
High 
Unknown 
Positive 
Positive 
Positive 
Unknown 
Positive 
Possible AD dementia    
Clinical evidence only Uninformative Conflicting / Indeterminate  
/ Unavailable 
Atypical clinical 
presentation with 
biomarkers for AD 
High Positive Positive 
Dementia unlikely due 
to AD 
Low Negative Negative 
Abbreviations: AD, Alzheimer’s disease; Aβ, amyloid-beta; PET, positron emission 
tomography; CSF, cerebrospinal fluid; FDG, 18fluorodeoxyglucose; sMRI, structural 
magnetic resonance imaging. 
Source : Adapted from McKhann GM, Knopman DS, Chertkow H, et al. The 
diagnosis of dementia due to Alzheimer’s disease : recommendations from the 
National Institute on Aging-Alzheimer’s Association workgroups on diagnostic 
guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263-9[6]. 
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As shown in table 1, a clinical diagnosis of probable AD based on only clinical 
criteria is of uninformative likelihood of AD pathology. The next level of certainty for a 
probable AD diagnosis is evidence of either amyloid deposition (detected on PET or 
in CSF) or neuronal injury (CSF tau levels, FDG-PET, or MRI atrophy patterns). This 
evidence increases the likelihood that the clinical syndrome of dementia is the result 
of underlying AD. The highest level of certainty is achieved when there is evidence of 
both amyloid deposition and neuronal injury in the presence of clinical evidence. 
There is also the category “possible AD,” with an atypical clinical course, but if both 
types of biomarkers (of amyloid deposition and neuronal injury) are positive, there is 
high likelihood of AD although it does not rule out second aetiology. Finally, with the 
wealth of available information on non-AD dementias, there is the category “unlikely 
due to AD,” which is appropriate if the person has clinical evidence, but 
accompanied by negative biomarkers for amyloid deposition and neuronal injury. 
 
So biomarkers are considered to be a potential adjunct to diagnosis, primarily 
for research purposes, that would serve to increase the certainty of the aetiology of 
the clinical diagnosis of AD. However, incorporating these biomarkers in clinical 
practice is not yet widely established. Although work has begun in standardizing CSF 
assays, PET imaging, and volumetric MRI measurements, there are not yet well-
validated, established normative values and calibration metrics for any of these 
biomarkers. Additional work remains to be done to standardize currently available 
biomarkers to enable optimal use in the clinical setting to develop more sensitive and 
specific biomarkers for early diagnosis, to track progression, and to monitor 
response to future disease-modifying therapy. 
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II. ATYPICAL PRESENTATION OF AD 
 
II.1. Evidence of AD heterogeneity in the literature 
 
Over the past years, there has been increasing awareness of slowly 
progressive focal cortical syndromes in which memory impairment is not a prominent 
feature and other symptoms predominate. Studies correlating clinical diagnosis and 
pathology in focal dementias have been few and have consisted mainly of either 
single case reports or relatively small series with particular cortical syndromes. A 
case series[50] reported on 13 patients with atypical and typical presentations of AD 
from a total of 52 patients reaching autopsy. It showed that pathologically proven AD 
can present with a range of cognitive symptoms and identified 3 main patterns: 
posterior cortical atrophy (PCA), primary progressive aphasia (PPA) and behavioural 
variant AD (bvAD). PPA is further classified in three subtypes: progressive nonfluent 
aphasia (PNFA), semantic dementia (SD) and logopenic aphasia (LPA).  
A large clinicopathological study[7] of typical AD and focal cortical syndromes 
attempted to estimate the frequency at which such syndromes are due to AD versus 
other pathologies was preformed. It showed that high proportion (just over a third) of 
focal cortical dementia syndromes is associated with AD pathology. The proportion 
of focal cortical syndromes associated to AD pathology was different according to 
their clinical presentations. 100% of PCA was found to be due to AD whereas 50% of 
corticobasal degeneration (CBD), 36% of PPA, 71% with mixed aphasia, 10% of SD 
and 7 % of bvAD were associated with AD pathologies. PPA is probably the 
commonest atypical presentation of AD with progressive nonfluent aphasia (PNFA) 
accounted for the majority of AD cases. Murray and his colleagues have shown by 
assessing the density and the distribution of neurofibrillary tangles on autopsy that 
atypical AD subtypes might account for about 25% of cases[52].  
Hence, there is a growing tendency in the literature suggesting a higher 
proportion of focal cortical presentations of AD pathology than previously recognized. 
These findings have implications for understanding the relationship between type of 
pathology and clinical dementia syndromes, as well as for early diagnosis and 
treatment. Several attempts have been made to better characterize those subtypes, 
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by neuropsychological profiles, biomarker profiles in the CSF and recently by 
neuroimaging. 
 
II.1.1 Imaging evidence of Heterogeneity 
 
In a comprehensive overview[53] authors presented the knowledge about 
different phenotypes of AD. They showed corresponding abnormalities on functional 
imaging suggesting that variations in the distribution of the pathogenic changes in 
AD account for some of the observed clinical differences. 
Foster and his colleagues[54] showed that patients with disproportionate failure of 
language function had markedly diminished metabolism in the left frontal, temporal, 
and parietal regions. Patients with predominant visuo-constructive dysfunction have 
shown evidenced a hypometabolic focus in the right parietal cortex. Patients with 
memory failure as the most apparent feature had no significant metabolic asymmetry 
in cortical regions. Verbal competency generally correlated with metabolic activity in 
the left frontal and temporal areas, while visuo-constructive test performance was 
linked to glucose utilization in the right parietal lobe. Pietrini et al.[55] showed the 
involvement of parietal and occipital cortices (including primary visual cortex) on 
18FDG-PET scan in patients with AD and visual disturbances at onset. Boxer and 
his colleagues[56] demonstrated significant right cortical grey matter loss in MRI 
imaging in the visuoconstructively impaired group. They concluded that right 
inferotemporal atrophy may serve as a neuroimaging marker of visual constructive 
impairment in mild to moderate AD. 
 
II.1.2. CSF biomarkers as an evidence of heterogeneity 
 
Some studies postulated that subgroups of AD might be identified by the 
cerebrospinal fluid (CSF) levels of proteins associated with senile (neuritic) plaques 
and neurofibrillary tangles[57]. The main biomarkers studied are t-tau, p-tau, and 
Aβ42 in the CSF[58]. However, current biomarkers do not account for all of the 
variance in AD; a more complete repertoire of biomarkers that more 
comprehensively assay the disease process is needed. 
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II.1.3. Neuropathological heterogeneity 
 
From a pathological point of view, evidence has been found to support 
hypotheses of Alzheimer’s heterogeneity. Neuropathological classification and 
scores exist such as the Braak's staging[16], describing the distribution of 
neurofibrillary tangles (NFT), the CERAD staging (Consortium to Establish a Registry 
Of Alzheimer’s disease) which describes the density of neuritic plaques[59] and the 
National Institute on Aging and the Reagan Institute of the Alzheimer's Association 
(NIA-RIA) criteria, being a synthesis of CERAD and Braak's criteria[60]. Regarding 
those criteria, neuropathological heterogeneity was observed: studies, which focused 
on neurofibrillar tangles (NFT) in AD revealed significantly different NFT densities in 
various areas of the cerebral cortex suggesting a possible existence of subgroups. 
 
II.2. Factors contributing to AD heterogeneity 
 
Factors, which might cause these clinical disparities, appear to be diverse. 
Three hypotheses have been proposed to explain neuropathological heterogeneity in 
AD: the presence of distinct subtypes of AD (“subtype hypothesis”), variation in the 
stage of the disease (“phase hypothesis”) and variation in the origin and progression 
of the disease (“compensation hypothesis”). For instance, Wilkosz and his 
colleagues[61] showed different cognitive impairment speeds and distinct trajectories 
of that deterioration speed may occur in different disease stages. Also the difference 
in cognitive reserve[62], depending on patient intellectual quotient, educational and 
occupational attainment could account for phenotypical disparities. But furthermore, 
different biological causes or processes that converge on a common final 
pathophysiological pathway might evoke heterogeneity: Ritchie and Touchon[63] 
showed that heterogeneity was due to the prevailing theory of the time, which held 
that clinical variation arose from observing the disease at different stages of 
progression (“phase hypothesis”), rather than truly distinct disease phenotypes 
(“subtype hypothesis”). In the same way, Armstrong and his colleagues examined 80 
cases of patients with AD and found that neuropathological differences were rather 
continuously distributed in contrast to the subtype hypotheses. Heterogeneity in 
plaque and tangle distribution correlated more with disease stage (phase hypothesis) 
rather than being explained by the presence of AD subtypes[64]. 
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Many factors have been shown to contribute to this variability such as the age 
of onset, the topography of AD pathology, and genetics. 
 
II.2.1. Age of Onset  
 
Koedam and his colleagues studied 270 patients with EOAD and 90 patients 
with LOAD. EOAD accounted for 32% of atypical AD in contrast to only 6% of typical 
AD[65]. In retrospect, this is consistent with earlier studies, wherein atypical 
subgroups of AD were significantly associated with younger age[66]. Moreover, Van 
der Vlies et al. showed, by assessing the changes in MMSE per year, that the course 
of the disease in the EOAD has a more rapid progression than the LOAD: change in 
MMSE per year was a mean of 2,4 in EOAD versus 1,7 in LOAD[67]. So these early-
onset individuals evince a more aggressive disease course, in distinction from the 
more gradual progression of typical AD, and in contrast to the very slow decline of 
temporal variant AD. A rare type of EOAD called familial Alzheimer’s disease (FAD), 
is caused by an autosomal dominant mutation in the amyloid precursor protein 
(APP), presenilin 1 (PSEN1), or presenilin 2 (PSEN2) genes[18]. Despite that most 
cases of FAD have early-onset, mutation in APP, PSEN1 and PSEN2 still account 
for only a small percentage of all EOAD cases although this percentage increases in 
patients with very early onset AD (VEOAD) i.e. less than 45 years old. 
 
II.2.2. Disease topography 
 
The distribution of AD pathology and associated atrophy varies among 
individuals and may affect phenotype. Neurofibrillary pathology has a stereotypical 
progression in AD that is encapsulated in the Braak staging scheme[16]. However, 
some AD cases are atypical and do not fit into this scheme. In a retrospective cohort, 
Murray et al. compared clinical and neuropathological features between typical and 
atypical AD cases: neurofibrillary tangle counts and senile plaque distribution 
showed that three pathologically distinct patterns of AD: hippocampal-sparing, limbic 
predominant, and 'typical' AD[52]. Hippocampal-sparing AD occurred in younger 
individuals (mean age 72 years, versus 79 for typical and 86 for limbic-predominant 
AD), which is consistent with the association between atypicality and EOAD. Also 
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hippocampal-sparing cases were more likely to have an atypical, non-amnestic 
clinical onset (30% of cases) versus individuals with typical pathological distribution, 
where this occurred less frequently (17%).  Hippocampal-sparing AD revealed the 
fastest rate of cognitive decline (-4.8 on MMSE per year, versus -2.8 for typical and -
1.4 for limbic-predominant AD). Other studies showed that early onset AD has 
atypical topography. With FDG-PET scan, patients with EOAD had more severe and 
more widespread hypometabolism than patients with LOAD: in a study, there was 
significantly lower glucose metabolism in precuneus, posterior cingulate, temporo-
parietal and occipital cortices[68].  
Structural MRI studies have shown that LOAD patients tend to have more prominent 
hippocampal volume loss than EOAD with more posterior areas more commonly 
affected in EOAD: precuneus, posterior cingulate and temporo-parietal areas[69]. 
 
II.2.3. Genetics 
 
Investigations for genetic predictors in AD have been significantly increased 
over the past years. In the autosomal dominant mutations causing FAD, mutations in 
PSEN1 and APP can both produce non-amnestic, atypical EOAD[70-71]. PSEN1 has 
been described in one patient with PNFA in addition to more typical amnestic AD[72]. 
A review reported cases with atypical findings associated with PSEN1 mutation[73]: 
PSEN1 mutation was reported in patients with spastic paraparesis, frontotemporal 
dementia, myoclonus with generalized seizures, and psychiatric disorders.  
Prominent early behavioural symptoms have also been reported in association with 
several PSEN2 mutations[74]. Extrapyramidal signs have been reported in 
association with several different PSEN1 mutations, particularly those causing very 
early onset disease and other neurological signs such as spastic paraparesis[75]. 
Guyant-Marechal and his colleagues showed intrafamilial diversity of AD phenotype 
with APP duplication: one member of the family with APP mutation complained with 
bradykinesia and hallucinations, another showed memory and behavioural changes, 
whereas the third member presented with memory decline followed by intracerebral 
haemorrhage from cerebral amyloid angiopathy (CAA)[76]. Rovelet-Lecrux and his 
colleagues also showed that APP can be associated with severe CAA presenting 
with haemorrhage and seizures along with memory decline[77]. Brains from such 
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individuals with APP duplication showed abundant parenchymal and vascular 
deposits of Aβ peptides. 
 
II. 3. AD subtypes 
 
The 3 main focal cortical presentations of AD, posterior cortical atrophy, 
primary progressive aphasia and behavioural variant AD will be explained in the 
following chapters. 
 
II.3.1. Posterior cortical atrophy (PCA) 
 
PCA is now a well-recognized focal dementia syndrome which appears to be 
nearly always due to AD pathology[50], but its regional distribution differs from typical 
AD. The immense majority of the patients with PCA do have AD with dementia with 
Lewy body, prion disease and τaupathies as major differential diagnosis[78]. Patients 
with PCA present progressive visual or visuospatial impairment in the absence of 
ophthalmologic impairment. On examination there is evidence of complex visual 
disorder: elements of Balint's syndrome, visual agnosia, dressing apraxia or 
environmental disorientation. But there is proportionately less memory loss or 
reduced verbal fluency[79]. PCA patients were further divided into two broad sub-
groups[80] : 
• the biparietal syndrome with  apraxia, visuospatial problems, agraphia, 
Balint's syndrome with preserved basic perceptual abilities, object 
recognition and reading (Figure II.1); 
• the occipitotemporal syndrome with alexia, apperceptive agnosia 
and/or prosopagnosia.  
Functional imaging shows biparieto-occipital hypoperfusion on SPECT scan[55] or 
hypometabolism on PET scans[81]. 
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Figure II.1: Brain MRI of a patient with troubles in performing manual tasks and an 
inability to write.  Coronal T1 (left) and axial T2 (right) with gross posterior cortical 
atrophy especially of the left parietal and temporal lobes. (Ross et al., 1996) [80] 
 
A third subtype is visual variant with primary visual failure and impairment of 
basic perceptual abilities. With only one previous pathologically proven case in the 
literature[82], this pathology appears to be even rarer than the 2 other syndromes.  
 
II.3.2. Primary Progressive aphasia (PPA) 
 
PPA is a clinical syndrome defined by the insidious onset and progressive 
dissolution of language skills. PPA pathologically usually occurs with one of the 
frontotemporal lobar degeneration (FTLD) spectrum pathologies. However, it has 
long been recognized that PPA syndrome may also be associated with AD[50][7]. 
Mesulam argued that PPA represents a distinct syndrome which can be 
distinguished from the aphasic presentation of AD by the clinical profile: preserved 
insight, social skills and episodic memory, visuospatial skills, reasoning, and 
comportment. In contrast to aphasia secondary to AD, which was associated with 
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early loss of insight and rapid deterioration in memory and other cognitive 
functions[83]. Diagnostic criteria for PPA are an insidious onset and progressive 
language difficulty for at least two years without behavioural changes, memory or 
visuospatial impairments[84]. In AD presenting as PPA, Galton et al.[50] reported a 
disproportionately high burden of plaques and tangles in the left temporal and inferior 
parietal cortex (language areas) with sparing of the hippocampus. On imaging, left 
temporal hypoperfusion and left perisylvian atrophy was seen. PPA can be classified 
into three distinct clinical variants based on language profiles, progressive nonfluent 
aphasia (PNFA), semantic dementia (SD), and the recently characterized logopenic 
or phonological variant (LPA)[85].  
Patients with PNFA have nonfluent speech characterized by agrammatism 
(i.e. hesitancy and effortfulness attributable to impaired planning of articulation), 
phonemic paraphasias, and relative preservation of memory.  In early disease MRI 
shows left inferior frontal and insula atrophy[86]. 
           In SD, speech fluency is preserved but there is a striking anomia, impaired 
word comprehension and deficits in non-verbal semantic association tasks such as 
sorting and grouping objects on basis of functional characteristics[87]. MRI shows 
asymmetrical anteroinferior temporal lobe atrophy. LPA is commonly associated with 
AD pathology[7].  
Patients with LPA have word-finding pauses and anomia as well as impaired 
speech repetition, particularly sentences, but grammar and articulation are 
preserved[88]. Verbal or phonological short-term memory is impaired[89]. MRI shows 
left temporo-parietal atrophy. 
 
II.3.3. Behavioural variant (bvAD) 
 
Patient may present with prominent behavioural symptoms such as 
disinhibition, apathy and lack of empathy, poor self-care, alterations of food 
preference, stereotypic behaviour, as well as executive dysfunction. They also 
present executive dysfunction. bvAD is an extremely rare EOAD subtype. Johnson 
and colleagues, who found 3 cases among 63 individuals with pathologically 
confirmed AD, first described it. Likewise, Alladi and his colleagues identified only 2 
instances among their 100 case series, of whom only one had a true dysexecutive 
syndrome, the other having only behavioural features[7]. Analysis of brain tissue 
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samples demonstrated that, despite comparable entorhinal, temporal, and parietal 
NFT loads, the frontal AD group showed a significantly higher NFT load in the frontal 
cortex than the typical AD group[91,92].  
 
This demonstrates the wide spectrum of AD presentations and the recognition 
of atypical presentations of AD is important when attempting to make an early 
accurate pre-morbid diagnosis of neurodegenerative disease. Latest 
pharmacological trials implicated that different subtypes within AD may exhibit 
different susceptibilities to specific treatment[93]. Hence, a superior characterization of 
the clinico-pathological heterogeneity and identification of predictive factors of 
disease progression should be able to improve our understanding of disease 
pathogenesis and allow better monitoring in therapeutic settings. 
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III. PRECLINICAL STAGE OF AD AND MILD COGNITIVE 
IMPAIRMENT (MCI) 
 
While specific changes in cognition are frequently observed in normal aging, 
there is increasing evidence that some forms of cognitive impairment are 
recognizable as an early manifestation of dementia[94].The utility of this paradigm 
centers around the recognition that dementia is not a dichotomous state. Our 
understanding of transitional states between normal cognition and dementia will 
improve the understanding of cognitive decline, facilitate early diagnosis, and 
ultimately benefit patients. 
  
III.1. Preclinical stage of AD 
 
Over the past years, it had been critical to better define the preclinical stage of 
AD, to determine the factors that best predict the emergence of clinical impairment 
and progression to eventual AD dementia, and to reveal the biomarker profile that 
will identify individuals most likely to benefit from early intervention. 
 
III.1.1. The continuum of AD  
 
The concept of AD pathogenesis has evolved from a static, binary view 
discriminating cognitive normality from dementia, towards a dynamic view that 
considers AD pathology as a long-lasting morbid process that takes place 
progressively over years, or even decades, before the first symptoms become 
apparent, and thus operating in a continuum between the two aforementioned 
extreme states. AD was perceived for the first time more as a dynamic process than 
a stationary state in the late 1980s, and the idea that the pathological process begins 
long before clinical symptoms become apparent has gained increasing interest[95]. 
The differences between normal aging and AD were clarified and formalized by 
Dubois and colleagues. They proposed a novel classification of AD[96], which 
describe a model of the clinical trajectory of AD (see figure III.1). It distinguishes 
three stages of the disease: preclinical AD, MCI, and AD due to dementia. 
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Figure III.1 : Model of the clinical trajectory of AD. 
 
The stage of preclinical AD precedes mild cognitive impairment (MCI) and 
encompasses the spectrum of: 
• presymptomatic autosomal dominant mutation carriers, 
• asymptomatic biomarker-positive carriers of one or more apolipoprotein 
E (APOE) alleles, 
• asymptomatic biomarker-positive older individuals at risk for 
progression to MCI due to AD and AD dementia, 
• biomarker-positive individuals who have demonstrated subtle decline 
from their own baseline that exceeds that expected in typical aging, but 
would not yet meet criteria for MCI. 
This diagram represents a hypothetical model for the pathological-clinical 
continuum of AD but does not imply that all individuals with biomarker evidence of 
AD-pathophysiological process will progress to the clinical phases of the illness. 
Also, AD should be defined as encompassing the underlying pathophysiological 
disease process, as opposed to having “AD” connote only the clinical stages of the 
disease. So to disambiguate the term “AD,” it was referred to evidence of the 
underlying brain disease process as AD-pathophysiological process (abbreviated as 
AD-P) and the clinical phases of the illness as “AD-Clinical” (abbreviated as AD-C), 
which include not only AD dementia but also individuals with MCI due to AD-P.  
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III.1.2. AD pathophysiological cascade 
 
AD-P is thought to begin years before the emergence of AD-C[97]. The extent 
to which biomarkers of AD-P predict a cognitively normal individual’s subsequent 
clinical course remains to be clarified. The difficulty in the field of AD is that it has not 
been established yet a firm link between the appearance of any specific biomarker in 
asymptomatic individuals and the subsequent emergence of clinical 
symptomatology. If however, it is possible to definitively determine the risk of 
developing AD dementia and the temporal course of clinical progression associated 
with AD-P in individuals without dementia or MCI, it will open a crucial window of 
opportunity to intervene with disease-modifying therapy. As an initial attempt to 
better understand the concept preclinical stage of AD, Sperling and colleagues 
proposed a theoretical model of the pathophysiological cascade of AD (Figure 
III.2)[98]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.2 : Hypothetical model of AD pathophysiological cascade 
Adapted from Sperling et al., 2011[98] 
 
So far, it is well known that Aβ accumulation is necessary but not sufficient to 
produce the clinical manifestations of AD. A widely accepted assumption is that AD 
begins with abnormal processing of amyloid precursor protein (APP), which then 
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leads to excess production or reduced clearance of Aβ in the cortex[99]. Genetic 
studies[19] have identified mutations in APP, PS1 and PS2 genes which are involved 
in the cleavage of Aβ from APP to generate amyloidogenic Aβ peptides, see chapter 
I.2.1). These mutations cause rare, dominantly inherited familial AD. Also, genetic 
and cell biological studies show increased production of more amyloidogenic Aβ 
peptides associated with dominantly inherited familial AD-linked mutations, providing 
strong support for the amyloid hypothesis[99], which postulate that Aβ peptides play a 
pivotal role in AD pathogenesis. Some investigators have also proposed that 
amyloid-independent mechanism may play an even earlier, or more central, role than 
Aβ peptides in the pathogenesis of AD such as synaptic, mitochondrial, metabolic, 
inflammatory, neuronal, cytoskeletal, and other age-related alterations[100]. Evidence 
also suggests that additional factors, such as brain and cognitive reserve[62], the 
presence of other age-related brain diseases, and genetic or environmental influence 
may modulate the relationship between AD-P and AD-C.  Environmental factors[101] 
such as cardiovascular risk factors (hypertension, hypercholesterolemia, 
diabetes)[102], depression[103], lack of engagement in cognitive[104], physical and social 
activity and lower education and socioeconomic status have been associated to 
increased risk of cognitive decline. 
 
III. 1.3. Model of dynamic biomarkers of the Alzheimer’s pathological cascade 
 
Jack and colleagues proposed a biomarker model[42]. This model 
hypothesized a specific sequence of biomarker abnormalities that began before any 
evidence of clinical symptoms, and a series of sigmoid curves to characterize the 
temporal dynamics of these biomarkers (Figure III.3). Also it postulated that markers 
of amyloid accumulation typically become abnormal first but, importantly, suggested 
that amyloid might be necessary but not sufficient to result in AD dementia. Also in 
this model, biomarkers of Aβ deposition become abnormal early, before 
neurodegeneration and clinical symptoms occur. Biomarkers of neuronal injury, 
dysfunction, and neurodegeneration become abnormal later in the disease. 
Cognitive symptoms are directly related to biomarkers of neurodegeneration rather 
than biomarkers of Aβ deposition. Finally, as was said earlier, demographic factors 
might influence the temporal trajectory of these hypothetical curves, including age, 
genetics, socio-economic factors such as education, and other indicators of cognitive 
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reserve. The temporal relationships among the biomarkers and with clinical disease 
stage constitute an array of testable hypotheses. 
 
 
Figure III.3 : Dynamic biomarkers of the Alzheimer’s pathological cascade. 
Aβ is identified by CSF Aβ42 or PET amyloid imaging. Tau-mediated neuronal injury 
and dysfunction is identified by CSF tau or FDG-PET. Brain structure is measured by 
structural MRI. Adapted from Jack et al., 2010[42] 
 
Also, a staging framework based on biomarkers was proposed to characterize 
patients at increasing risk of progression toward MCI and dementia. Stage 1 is 
characterized as asymptomatic cerebral amyloidosis; stage 2 is amyloidosis plus 
neurodegeneration; and stage 3 is amyloidosis, neurodegeneration, and evidence of 
very subtle change in cognition or behaviour but is not sufficient to be diagnosed with 
MCI. 
 
III.2. Mild Cognitive Impairment (MCI) 
 
III.2.1. Definition and progression of MCI  
 
Over the past three decades it has become abundantly clear that the cognitive 
deficits that accompany pathophysiological process of AD evolve gradually with 
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dementia representing the end stage of many years of pathology accumulation. 
When the cognitive impairment is sufficiently great, such that there is interference 
with daily function, the patient is diagnosed with AD dementia. As AD is a slow, 
progressive disorder, with no fixed events that define its onset, it is particularly 
challenging for clinicians to identify transition points for individual patients. Thus, the 
point at which an individual transition from the asymptomatic phase to the 
symptomatic MCI phase, or from the symptomatic MCI phase to dementia onset are 
difficult to identify. 
The term MCI has arisen since the mid 1990’s and stand for the symptomatic 
predemented phase of AD: the gradual impairments of cognitive function that 
precede the point where significant interference in daily activities occur[105]. So MCI 
refers to the clinical condition between normal aging and AD in which persons 
experience memory loss to a greater extent than one would expect for age, yet they 
do not meet currently accepted criteria for clinically probable AD. Patients with MCI 
have a far higher rate of developing dementia than cognitively normal persons, but at 
the individual level, prognosis is variable: sometimes persons with MCI do not 
worsen and a few even revert back to cognitive normality. The variable prognosis in 
MCI is one reason why the term “MCI” has caught on: not only does it denote a 
sense of severity at the mildest level, it also conveys uncertainty of prognosis. 
Identification of the subset of patients with MCI at highest risk to progress to more 
severe cognitive impairment is a very important goal for research and future clinical 
care[106]. Quantisation the degree of cognitive impairment by traditional history-
taking, brief mental status testing, and more detailed neuropsychological 
assessment are necessary and informative first steps. Moreover, It is important that 
people with AD be identified as early as possible, so that they can benefit from 
treatments in development that slow down the progression of the disease. 
 
III.2.2. Criteria for the clinical and cognitive syndrome 
 
Largely informed by the advances in biomarker research discussed above 
and by increasing recognition of early stages of clinical impairment, a number of 
expert groups have worked over the past decade to develop new diagnostic criteria. 
The National Institute on Aging and the Alzheimer’s Association convened a working 
group to revise the diagnostic criteria for MCI[107]. The diagnosis of MCI is based 
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upon core clinical criteria that can be applied broadly, in any setting, without the 
need of highly specialized tests and/or procedures. These criteria are based on 3 
main ideas:  
• Concern from the family or physician regarding a change in cognition in 
comparison with the person’s previous level or evidence of 
intraindividual change on serial evaluations.  
• The patient present impairment in one or more cognitive domains that 
is greater than would be expected for the patient’s age and educational 
background. This change can occur in a variety of cognitive domains, 
including memory, executive function, attention, language, and 
visuospatial skills. Impairment in episodic memory (the ability to learn 
and retain new information) is seen most commonly in MCI patients 
who subsequently progress to a diagnosis of AD dementia. 
• Despite this cognitive impairment, there should be preservation of 
independence in functional abilities. Indeed, these cognitive changes 
should be sufficiently mild that there is no evidence of a significant 
impairment in social or occupational functioning. 
Furthermore, evidence of progressive decline in cognition provides additional 
evidence that the individual has “MCI due to AD”. Thus, it is important to obtain 
longitudinal assessments of cognition, whenever possible by serial evaluations of 
cognition but it may not be feasible in a particular circumstance. This is inherently a 
clinical judgment made by a skilled clinician on the basis of the individual 
circumstances of the patient and the description of daily affairs of the patient 
obtained from the patient and from a knowledgeable informant. Finally, as the similar 
strategy to that one that is use to diagnose AD-dementia, physicians must rule out 
other cerebrovascular disease that could account for the decline in cognition. So, the 
differentiation of dementia from MCI rests on whether there is substantial 
interference in the ability to function at work or in usual daily activities. This is a 
clinical judgment.  
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III.2.3. Objective clinical assessment of cognitive impairment: neuropsychological 
tests 
 
Cognitive testing can assess objective evidence of impairment in one or more 
cognitive domains. Impairment in episodic memory is most commonly seen in MCI 
patients who subsequently progress to a diagnosis of AD dementia. There are a 
variety of episodic memory tests that are useful for identifying those MCI patients 
who have a high likelihood of progressing to AD dementia within a few years. 
Examples of such tests include the Free and Cued Selective Reminding Test, the 
Rey Auditory Verbal Learning Test, and the California Verbal Learning Test (CVLT).  
Other episodic memory measures include: immediate and delayed recall of a 
paragraph such as the Logical Memory I and II of the Wechsler Memory Scale 
Revised[108] and immediate and delayed recall of nonverbal materials, such as the 
Visual Reproduction subtests of the Wechsler Memory Scale-Revised I and II. The 
Mini Mental State Examination[11] is used as a general measurement of dementia. 
Because other cognitive domains can be impaired among individuals with 
MCI, it is important to examine domains in addition to memory. Many validated 
clinical neuropsychological measures are available to assess these cognitive 
domains. These include:  
• executive functions (set-shifting, reasoning, problem-solving, planning): 
Trail Making Test; 
• language (naming, fluency, expressive speech, and comprehension) : 
the Boston Naming Test, letter and category fluency; 
• visuospatial skills : figure copying; 
• attentional control : digit span forward. 
 
III.2.4. MCI Classification: Incorporating biomarkers in clinical practice 
 
The National Institute on Aging and the Alzheimer’s Association gave 
recommendations for MCI classification[107]. As shown in Table III.1 the first level of 
diagnostic certainty for MCI involves having the clinical evidence alone. The next 
level of certainty requires positive evidence of either amyloid deposition or neuronal 
injury biomarkers. The highest level of confidence that MCI is caused by AD is 
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derived when the clinical syndrome is accompanied by positive evidence for both 
amyloid deposition and neuronal injury. As with dementia, the likelihood of a clinical 
syndrome not being caused by AD-P is low if the biomarkers are negative. At this 
point, only the diagnosis of MCI should be used in practice.  
 
Table III.1 : Diagnostic Criteria for MCI 
Diagnosis Likehood of 
AD aetiology 
Aβ 
(PET or CSF) 
Neuronal injury 
(tau, FDG-PET, sMRI) 
MCI Uninformative Conflicting / Indeterminate / Untested 
MCI due to AD 
Intermediate likehood 
Intermediate 
Intermediate 
Positive 
Untested 
Untested 
Positive 
MCI due to AD 
High likehood 
High Positive Positive 
MCI  
Unlikely due to AD 
Low Negative Negative 
Abbreviations: MCI, Mild Cognitive Impairment ; AD, Alzheimer’s disease; Aβ, 
amyloid-beta; PET, positron emission tomography; CSF, cerebrospinal fluid; FDG, 
18fluorodeoxyglucose; sMRI, structural magnetic resonance imaging. 
Source : Adapted from Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of 
mild cognitive Impairment due to AD: recommendations from the National Institute 
on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for AD. 
Alzheimer Dement. 2011;7(3):270-9[107] 
 
However, nowadays biomarkers are deemed to be primarily for research use 
because several important issues about incorporating biomarkers into clinical 
practice exist, in particular, the need for standardization across centers. Although 
work has begun in standardizing CSF assays, PET imaging, and volumetric MRI 
measurements, there are not yet well-validated, established normative values and 
calibration metrics for any of the biomarkers. Additional work is required to make 
these biomarkers more easily interpretable to physicians in a variety of clinical 
settings. 
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DISCUSSION 
 
The diagnosis of AD, and its neuropsychiatric sequelae, presents significant 
challenges for the clinicians because of the wide spectrum of the disease and its 
heterogeneous presentation. Indeed, it has been increasingly understood and 
recognized through several studies that AD has several atypical variants and can be 
identified in 3 main patterns: posterior cortical atrophy (PCA), primary progressive 
aphasia (PPA) and behavioural variant AD (bvAD). Moreover in the last decade, it 
has been shown that, during several years preceding the diagnosis of AD there is a 
gradual cognitive decline with a continuum in the disease and that the three stages 
exists: preclinical AD, MCI and dementia due to AD. This is why the new criteria 
issued in 2011 by the National Institute on Aging for diagnosing the AD spectrum 
were designed to help clinicians characterize individuals as early as possible in the 
course of the disease to allow for early intervention and prevention of subsequent 
neuronal damage. The criteria are also necessary for designing clinical trials for new 
therapies to prevent neuronal destruction.  
Finally, recent studies assessed that biomarkers can be used to diagnose AD, 
its clinical variants, and its very early stage. It can also provide objective and reliable 
measures of disease progress. However, nowadays, the difficulty in the field of AD is 
that we have not yet established a firm link between the appearance of any specific 
biomarker in asymptomatic individuals and the subsequent emergence of clinical 
symptomatology. However, if we can definitively determine the risk of developing AD 
dementia and the temporal course of clinical progression associated with AD-P in 
individuals without dementia or MCI, we will open a crucial window of opportunity to 
intervene with disease-modifying therapy.  
We should be open to the idea that, similar to cardiac disease and cancer 
treatment, AD can be diagnosed preclinically before significant cognitive impairment 
by the presence of biomarker evidence of AD pathologic change, and that this and 
other biomarkers may eventually guide therapy prior to the onset of symptoms. The 
overarching therapeutic objective of these preclinical studies would be to treat early 
pathological processes (e.g., lower Aβ burden or decrease neurofibrillary tangle 
pathology) to prevent subsequent neurodegeneration and eventual cognitive decline.  
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CONCLUSION 
 
AD generally presents as a slowly progressive amnestic syndrome in later life, 
but there are several conditions that can mimic AD; conversely AD can mimic a 
range of other conditions. The high prior likelihood that an elderly individual with 
cognitive impairment has AD should not preclude consideration of other causes, and 
in particular it is always important to consider 'reversible' or treatable conditions, 
even if they are rare. Aside from endogenous variation in the AD phenotype, a 
further issue (particularly in older patients) is the real possibility of mixed pathology, 
eg, superadded vascular damage or Lewy body pathology, which may modify the AD 
phenotype. In many cases, careful history taking and bedside assessment can help 
to define atypical or unusual cases, but standard investigations, particularly MRI and 
neuropsychology, can be very useful in assessing the likelihood of AD versus other 
conditions. 
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